PCSK9 competition weighs on Aegerion

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) fell $2.48 (19%) to $10.64 on Tuesday after it said in a postmarket Monday earnings call that PCSK9 inhibitors are starting to dent sales of its lipid-lowering agent Juxtapid lomitapide. The company said switches to PSCK9 inhibitors from Juxtapid were higher than expected in 3Q15.

Juxtapid sales were $58.8 million in 3Q15, up from $43.7 million in 3Q14. Aegerion attributed the gain to increased average sales price and higher international sales. Total product sales were $67.3 million, up from $43.7 million in 3Q14. ...